QUEST DIAGNOSTICS INC (DGX): 10-Q filed July 23, 2026

AI analysis of the 10-Q that QUEST DIAGNOSTICS INC filed with the U.S. SEC on July 23, 2026, grounded in the primary-source EDGAR filing.

• Major Integration Risks Ahead: Corewell Health acquisition (closed Jan 31, 2026) introduces significant execution risk with undisclosed earnout obligations and customer relationship intangibles vulnerable to impairment if synergy targets slip.

• Volatile Contingent Liabilities: Haystack Oncology contingent consideration remains a material moving target, with Q2 2026 remeasurement driven by discount rate and comparable company volatility—creating earnings unpredictability.

• Restructuring Execution Uncertainty: Invigorate program's material accrued liabilities depend on achieving cost savings across COGS and SG&A; shortfalls would pressure margins and require future charges.

• Cautious Management Tone: Neutral sentiment with undertones of caution suggests leadership acknowledges integration/restructuring headwinds but lacks confidence in full visibility to outcomes.

• Investor Watchpoint: Monitor upcoming earnings for earnout adjustments, customer relationship impairment testing, and Invigorate savings realization—misses on any front could trigger material non-cash charges.

Filing analysis — key questions

Answers are generated from this SEC filing and StockHuntr's analysis. Not investment advice.

What does QUEST DIAGNOSTICS INC (DGX)'s 10-Q filed July 23, 2026 say?

Quarterly Financial Results for Q2 2026 - Contains consolidated financial statements for the six-month period ended June 30, 2026 and the three-month period ended June 30, 2026, compared to the same periods in 2025 Balance Sheet and Equity Information - Presents detailed stockholders' equity components including common stock, additional paid-in capital, retained earnings, accumulated other…

Is DGX's 10-Q bullish or bearish?

Our analysis rates this filing CAUTIOUS. Quest Diagnostics faces an ELEVATED concern profile driven by multiple material risks in a INCREASING trend. The two severity-7 risks—contingent consideration valuation volatility and industry-wide reimbursement/competitive pressures—represent meaningful…

How concerning is DGX's latest 10-Q?

Concern level: HIGH (6.8/10). Key factors: Two high-severity risks identified (severity 7/10): Haystack Oncology contingent consideration valuation volatility and medical laboratory industry reimbursement/competitive pressures; Risk trend is INCREASING with overall risk score of 6.8, indicating deteriorating risk profile; Haystack Oncology contingent consideration shows active fair value…

What are the main risks flagged in DGX's 10-Q?

Notable risk changes: Corewell Health acquisition closed January 31, 2026 - new integration risk and potential earnout liabilities not fully disclosed; customer relationship intangibles subject to impairment risk if synergies fail to materialize; Haystack Oncology contingent consideration remains material liability with high fair value volatility - Q2 2026 shows active remeasurement driven by changes in discount…

What is the 30-day stock outlook for DGX after this filing?

The model predicts DGX will underperform the S&P 500 by about 0.0% over 30 days. This is model analysis for research, not investment advice.

About this analysis

Primary source:
View this 10-Q on SEC EDGAR
Additional data:
Yahoo Finance (market data)
Method:
StockHuntr analyzes filings with AI — see our methodology.
Analysis as of:
July 23, 2026
Published by:
StockHuntr

For research and education only. Nothing here is investment advice.

📄

Fetching Filing from SEC

Downloading filing HTML from SEC.gov...

15% Complete
1
Fetch filing from SEC
2
Parse document sections
3
Fetch prior filing
4
Analyze risk factors
5
Analyze management sentiment
6
Extract financial metrics
7
Compare to analyst consensus
8
Run ML prediction model
9
Finalize analysis

Note: Analysis typically takes 30-60 seconds. We're fetching real SEC filing data and running AI analysis on the actual content.